About Vigil Neuroscience
Vigil Neuroscience is a company based in Cambridge (United States) founded in 2020 was acquired by Sanofi in May 2025. It operates as a HealthTech. Vigil Neuroscience has raised $140 million across 3 funding rounds from investors including ARE, Sanofi and Citadel. The company has 56 employees as of February 28, 2023. Vigil Neuroscience offers products and services including TREM2 Activators. Vigil Neuroscience operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
- Headquarter Cambridge, United States
- Employees 56 as on 28 Feb, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vigil Neuroscience, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$84.26 M (USD)-2as on Dec 31, 2024
-
EBITDA
-$89.68 M (USD)-1as on Dec 31, 2024
-
Total Equity Funding
$140 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
Jul 03, 2024
-
Investors
ARE
& 14 more
-
Employee Count
56
as on Feb 28, 2023
-
Acquired by
Sanofi
(May 21, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vigil Neuroscience
Vigil Neuroscience offers a comprehensive portfolio of products and services, including TREM2 Activators.
Therapeutics are developed to activate TREM2 in microglia.
People of Vigil Neuroscience
Unlock access to complete
Unlock access to complete
Funding Insights of Vigil Neuroscience
Vigil Neuroscience has successfully raised a total of $140M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vigil Neuroscience
Vigil Neuroscience has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Sanofi and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Vigil Neuroscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vigil Neuroscience
Investment portfolio details for Vigil Neuroscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vigil Neuroscience
Detailed financials for Vigil Neuroscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vigil Neuroscience Comparisons
Peer comparison for Vigil Neuroscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vigil Neuroscience
Vigil Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Vigil Neuroscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vigil Neuroscience
Complete news archive for Vigil Neuroscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vigil Neuroscience
Vigil Neuroscience was founded in 2020.
Vigil Neuroscience is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ivana Magovcevic-Liebisch is the current CEO of Vigil Neuroscience.
Vigil Neuroscience is a funded company, having raised a total of $140M across 3 funding rounds to date.
As of Feb 28, 2023, the latest employee count at Vigil Neuroscience is 56.
Vigil Neuroscience is engaged in developing disease-modifying therapeutics for rare and common neurodegenerative diseases by targeting microglia, the brains sentinel immune cells. The company is driven by a precision medicine approach, initially focusing on genetically defined patient subpopulations to activate and restore microglial function. Efforts are directed toward addressing high unmet needs in disease pathology, starting with rare diseases and expanding into more common neurodegenerative conditions. Therapeutic candidates are designed to activate TREM2, a key microglial receptor linked to brain health maintenance and neurodegeneration prevention.
Vigil Neuroscience's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
Vigil Neuroscience offers TREM2 Activators.
Vigil Neuroscience has 15 investors. Key investors include ARE, Sanofi, Citadel, Orbimed, and Atlas Venture.